KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Non-Current Assets (2016 - 2025)

Eli Lilly (LLY) has disclosed Non-Current Assets for 17 consecutive years, with $56.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 23.65% year-over-year to $56.8 billion, compared with a TTM value of $208.9 billion through Dec 2025, up 22.46%, and an annual FY2025 reading of $56.8 billion, up 23.65% over the prior year.
  • Non-Current Assets was $56.8 billion for Q4 2025 at Eli Lilly, up from $52.9 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $56.8 billion in Q4 2025 and bottomed at $29.8 billion in Q3 2022.
  • Average Non-Current Assets over 5 years is $38.1 billion, with a median of $34.2 billion recorded in 2023.
  • The sharpest move saw Non-Current Assets fell 1.85% in 2022, then rose 26.59% in 2024.
  • Year by year, Non-Current Assets stood at $30.4 billion in 2021, then rose by 3.63% to $31.5 billion in 2022, then rose by 21.69% to $38.3 billion in 2023, then grew by 20.1% to $46.0 billion in 2024, then increased by 23.65% to $56.8 billion in 2025.
  • Business Quant data shows Non-Current Assets for LLY at $56.8 billion in Q4 2025, $52.9 billion in Q3 2025, and $51.1 billion in Q2 2025.